Compass therapeutics to present phase 1 data for ctx-471, a novel cd137 agonist antibody, demonstrating anti-tumor activity in patients who have progressed on approved pd-1 or pd-l1 inhibitors at the american society of clinical oncology (asco) annual meeting 2024

Boston, may 23, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel anti-cd137 agonist antibody, ctx-471, in patients with progressive disease following pd-1/pd-l1 inhibitors in metastatic or locally advanced malignancies.
CMPX Ratings Summary
CMPX Quant Ranking